01 July 2026
01 July 2026
Topline results from RISE3 are expected in H2 2026.
The decision was based on findings from the Phase III PANOVA-3 clinical trial.
Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.
The Opuswave system combines the deep vessel visualisation of IVUS with the high-resolution surface imaging of OFDI.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
